title: FGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation.
abstract: Aberrant fibroblast growth factor receptor 3 (FGFR3) signaling disrupts chondrocyte proliferation and growth plate size and architecture, leading to various chondrodysplasias or bone overgrowth. These observations suggest that the duration, intensity and cellular context of FGFR signaling during growth plate chondrocyte maturation require tight, regulated control for proper bone elongation. However, the machinery fine-tuning FGFR signaling in chondrocytes is incompletely defined. We report here that neurofibromin, a Ras-GAP encoded by Nf1, has an overlapping expression pattern with FGFR1 and FGFR3 in prehypertrophic chondrocytes, and with FGFR1 in hypertrophic chondrocytes during endochondral ossification. Based on previous evidence that neurofibromin inhibits Ras-ERK signaling in chondrocytes and phenotypic analogies between mice with constitutive FGFR1 activation and Nf1 deficiency in Col2a1-positive chondrocytes, we asked whether neurofibromin is required to control FGFR1-Ras-ERK signaling in maturing chondrocytes in vivo. Genetic Nf1 ablation in Fgfr1-deficient chondrocytes reactivated Ras-ERK1/2 signaling in hypertrophic chondrocytes and reversed the expansion of the hypertrophic zone observed in mice lacking Fgfr1 in Col2a1-positive chondrocytes. Histomorphometric and gene expression analyses suggested that neurofibromin, by inhibiting Rankl expression, attenuates pro-osteoclastogenic FGFR1 signaling in hypertrophic chondrocytes. We also provide evidence suggesting that neurofibromin in prehypertrophic chondrocytes, downstream of FGFRs and via an indirect mechanism, is required for normal extension and organization of proliferative columns. Collectively, this study indicates that FGFR signaling provides an important input into the Ras-Raf-MEK-ERK1/2 signaling axis in chondrocytes, and that this input is differentially regulated during chondrocyte maturation by a complex intracellular machinery, of which neurofibromin is a critical component.
authors.affiliation: Department of Pharmacology, Vanderbilt Center for Bone Biology.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Karolak
authors.affiliation: Department of Pharmacology, Vanderbilt Center for Bone Biology, Department of Medicine and.
authors.forename: Xiangli
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Pharmacology, Vanderbilt Center for Bone Biology, Department of Medicine and Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA florent.elefteriou@vanderbilt.edu.
authors.forename: Florent
authors.initials: F
authors.lastname: Elefteriou
mesh_terms: D000818:Animals; D019902:Chondrocytes / Q000378:metabolism* / Q000473:pathology; D020219:Chondrogenesis / Q000235:genetics; D024043:Collagen Type II / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D055786:Gene Knockout Techniques; D006132:Growth Plate / Q000378:metabolism; D006984:Hypertrophy; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D025542:Neurofibromin 1 / Q000235:genetics / Q000378:metabolism*; D010010:Osteoclasts / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects / Q000235:genetics; D010641:Phenotype; D010671:Phenylurea Compounds / Q000494:pharmacology; D021381:Protein Transport; D011743:Pyrimidines / Q000494:pharmacology; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction
chemical_list: C447413:Col2a1 protein, mouse; D024043:Collagen Type II; D025542:Neurofibromin 1; D010671:Phenylurea Compounds; D011743:Pyrimidines; C568950:infigratinib; D051496:Receptor, Fibroblast Growth Factor, Type 1; D051498:Receptor, Fibroblast Growth Factor, Type 3